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Abstract
Introduction: The purpose of this study was to determine whether maraviroc, a human CC chemokine receptor 5
(CCR5) antagonist, is safe and effective in the treatment of active rheumatoid arthritis (RA) in patients on
background methotrexate (MTX).
Methods: This phase IIa study comprised two distinct components: an open-label safety study of the
pharmacokinetics (PK) of MTX in the presence of maraviroc, and a randomized, double-blind, placebo-controlled,
proof-of-concept (POC) component. In the PK component, patients were randomized 1:1 to receive maraviroc 150
or 300 mg twice daily (BID) for four weeks. In the POC component, patients were randomized 2:1 to receive
maraviroc 300 mg BID or placebo for 12 weeks. Patients were not eligible for inclusion in both components.
Results: Sixteen patients were treated in the safety/PK component. Maraviroc was well tolerated and there was no
evidence of drug-drug interaction with MTX. One hundred ten patients were treated in the POC component. The
study was terminated after the planned interim futility analysis due to lack of efficacy, at which time 59 patients
(38 maraviroc; 21 placebo) had completed their week 12 visit. There was no significant difference in the number of
ACR20 responders between the maraviroc (23.7%) and placebo (23.8%) groups (treatment difference -0.13%; 90% CI
-20.45, 17.70; P = 0.504). The most common all-causality treatment-emergent adverse events in the maraviroc
group were constipation (7.8%), nausea (5.2%), and fatigue (3.9%).
Conclusions: Maraviroc was generally well tolerated over 12 weeks; however, selective antagonism of CCR5 with
maraviroc 300 mg BID failed to improve signs and symptoms in patients with active RA on background MTX.
Trial Registration: ClinicalTrials.gov: NCT00427934
Introduction
Maraviroc is an orally active, noncompetitive, reversible
antagonist of the human CC chemokine receptor 5
(CCR5), which is the primary chemokine receptor
expressed by rheumatoid synovial T cells [1,2]. It has
been approved for use in combination with other antire-
troviral agents in treatment-experienced adult patients
who have been infected with only CCR5-tropic HIV-1
and who have evidence of viral replication and HIV-1
strains resistant to multiple antiretroviral agents [3,4].
Studies have demonstrated reductions in viral load at
maraviroc doses ranging from 150 to 600 mg twice daily
(BID) (based on concomitant medications) [5]. In addi-
tion to having a role as a co-receptor for CCR5 HIV
viral binding and cell entry, the CCR5 receptor has a
role in the trafficking, localization, and differentiation of
leukocytes [6,7]. In rheumatoid arthritis (RA), chemo-
kine upregulation is associated with tissue and joint
destruction and increased levels of CCR5 receptor
ligands (Regulated on Activation, Normal T-cell
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Expressed, and Secreted [RANTES], macrophage inflam-
matory protein [MIP]-1a, and MIP-1b) in the synovial
fluid [8-11]. It is hypothesized that, by preventing che-
mokine-induced CCR5 activation, cellular retention at
sites of inflammation and activation of synovial fibro-
blasts and chondrocytes will be reduced, yielding both
symptomatic relief and a reduction in joint destruction
in patients with RA [1].
Preclinical work in a rhesus monkey collagen-induced
arthritis model demonstrated suppression of C-reactive
protein (CRP) and altered antibody response toward
type II collagen with a CCR5-antagonist, SCH-X [12]. In
another preclinical study, use of Met-RANTES, which
blocks both CCR1 and CCR5, caused the amelioration
of adjuvant-induced arthritis in Lewis rats [13]. Further-
more, there is evidence to suggest that the CCR5Δ32
mutation, which leads to reduced CCR5 expression at
the cell surface, is associated with a protective effect in
patients with RA [14-16]; however, this finding has not
been consistent [17,18].
This study comprised two distinct components. The
primary objectives of the first component were to evalu-
ate the safety and tolerability of maraviroc 150 and 300
mg BID administered for 4 weeks to patients with active
RA on stable background treatment with methotrexate
(MTX), characterize the pharmacokinetics (PK), and
investigate potential drug-drug interactions (DDIs)
between maraviroc and MTX after 4 weeks of co-
administration. The primary objective of the second
component was to assess the safety and efficacy of mar-
aviroc 300 mg BID (versus placebo) in patients with
active RA on stable background treatment with MTX
after 12 weeks of treatment.
Materials and methods
This study was sponsored by Pfizer Inc (New York, NY,
USA) and was conducted in 41 centers in nine countries
(Australia, Germany, India, Italy, Mexico, Portugal,
Spain, Ukraine, and the US). The final protocol, amend-
ments, and informed consent documentation were
reviewed and approved by the institutional review boards
and the independent ethics committees at each of the
investigational centers participating in the study. This
study was conducted in compliance with the ethical prin-
ciples originating in or derived from the Declaration of
Helsinki and in compliance with the International Con-
ference on Harmonization Good Clinical Practice guide-
lines. All patients provided informed consent prior to
screening and enrollment. The trial is registered as
http://ClinicalTrials.gov number NCT00427934.
Patients
Eligible patients had to be at least 18 years old, had to
have an active-RA diagnosis based on the American
College of Rheumatology (ACR) 1987 revised criteria,
and had to meet the ACR 1991 Revised Criteria for Glo-
bal Functional Status in RA (class I, II, or III). Patients
had to be receiving MTX therapy for at least 12 weeks
prior to study entry at a stable dose for at least 4 weeks
prior to study entry which remained unchanged
throughout the 12 week treatment period. MTX dosage
had to be at least 10 mg/week and not more than 25
mg/week (oral or parenteral) unless documented intoler-
ance required a lower dose. In the safety/PK component,
there were no disease activity requirements. However, in
the proof-of-concept (POC) component, a minimum
disease activity requirement of at least six tender/painful
joints on motion (28-joint count), at least six swollen
joints (28-joint count), a CRP of at least 0.7 mg/dL, or
an erythrocyte sedimentation rate of at least 28 mm/
hour was necessary for inclusion.
Patients were excluded if they were receiving or
unable to washout other medications that could inter-
fere with disease activity assessments. Such medications
would include the following: auranofin, injectable gold,
sulfasalazine, d penicillamine, azathioprine, cyclosporine,
high-dose corticosteroids (> 10 mg/day prednisone or
the equivalent), anakrinra, etanercept, herbal supple-
ments that included fish oil, or leflunomide (within 4
weeks); infliximab, adalimumab, or any experimental RA
therapy (within 8 weeks); abatacept (within 3 months);
or rituximab (within 12 months). Other exclusion cri-
teria included the following: a history of chronic life-
threatening infection; severe, progressive, and/or uncon-
trolled renal, hepatic, hematological, gastrointestinal,
endocrine, pulmonary, cardiac, or neurologic disease;
tuberculosis without treatment and/or positive tubercu-
lin reaction without known Bacilli Calmette-Guérin vac-
cination; positive homozygous CCR5Δ32 mutation;
history or evidence of postural hypotension; New York
Heart Association class III-IV congestive heart failure
requiring treatment; mean corrected QT (QTc) interval
of greater than 450 ms; evidence of any current active
infection; or history of cancer and in remission for less
than 3 years.
Study design
This phase IIa study investigated oral maraviroc in
patients who had RA and who were receiving background
MTX. The study comprised two components: an open-
label safety/PK component and a randomized, double-
blind, placebo-controlled POC component (Figure 1).
Safety/pharmacokinetics component
This component comprised a 4-week, open-label study
conducted only in the US. Two dose levels of oral mara-
viroc (150 mg and 300 mg BID) were investigated in
patients who had no disease activity requirements and
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who were on stable doses of background MTX (Figure
1A). This component of the study was conducted to
confirm the safety and lack of clinically significant DDIs
when maraviroc was co-administered with MTX.
Patients enrolled in this portion of the study were not
eligible for inclusion in the POC component of the
study, and replacements could be recruited if patients
were discontinued from the study for reasons other than
safety.
Blood samples were obtained at screening visits and
were used to assess each patient’s steady-state MTX PK
parameters. Additional blood samples were collected at
week 1 in order to assess steady-state MTX PK para-
meters in the presence of maraviroc. PK analyses for
potential DDIs, coupled with weekly safety monitoring,
were used by an internal risk management committee to
select a dose for the POC component of the study. If
the safety and PK profiles of the 150- and 300-mg doses
were similar and there was no evidence of DDI with
MTX, the 300-mg dose would be selected for the 12-
week POC component.
Proof-of-concept component
Eligible patients on stable background doses of MTX
were randomly assigned 2:1 to either oral maraviroc 300
mg BID or placebo BID for 12 weeks (Figure 1B). Safety
and efficacy assessments were performed at baseline and
at weeks 1, 2, 4, 8, and 12, and a follow-up visit took
place at week 16. An interim futility analysis was
planned after approximately 57 patients had completed
their week 12 visit and was performed by an internal
data-monitoring committee.
Treatments
All doses of maraviroc were self-administered and taken
at approximately 12 hour intervals on an empty stomach,
specifically 1 hour before a meal or 4 hours after the last
meal. Both maraviroc and placebo treatments were added
to ongoing stable background MTX therapy.
Concomitant treatments
All medications taken 28 days prior to the first dose of
study treatment had to be recorded. Patients were per-
mitted to continue on their stable background RA ther-
apy, which could have included nonsteroidal anti-
inflammatory drugs and cyclooxygenase-2 inhibitors,
low-dose oral corticosteroids (not more than 10 mg of
prednisone per day or the equivalent), and opioid analge-
sics (not more than 30 mg of oral morphine per day or
the equivalent). Concomitant use of not more than 325
mg/day of aspirin was acceptable if taken for nonarthritic
reasons. In addition, concomitant use of folic acid was
encouraged for patients receiving MTX. Use of moderate
to strong CYP3A4 inhibitors/inducers and grapefruit
products was prohibited during the study. In the POC
component, patients on stable doses of antimalarials
(chloroquine and hydroxychloroquine) for at least 60
days were allowed to continue these medications.
Rescue medications
Acetaminophen (paracetamol) (not more than 2.6 g/day
for not more than four consecutive days) was allowed as a
rescue medication. If a patient was already taking stable
background doses of acetaminophen, the dose could be
increased up to 2.6 g/day for up to four consecutive days
for rescue purposes. Rescue medication was not permitted
within 24 hours of a study visit. Patients who required res-
cue medication for more than four consecutive days were
discontinued from the study for lack of efficacy.
Evaluations
Safety/pharmacokinetics component
In addition to the general safety evaluations outlined
below, maraviroc and MTX PK parameters were
Figure 1 Study design. (A) Open-label safety/PK component (4 weeks). (B) Double-blinded proof-of-concept component (12 weeks). *Patients
without any disease activity requirements. BID, twice daily; MTX, methotrexate; PK, pharmacokinetics.
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calculated for each patient for each treatment by using
noncompartmental analysis of concentration-time data.
Peak plasma concentration (Cmax) and time to Cmax
(Tmax) were determined by inspection of the individual
concentration-time profiles. The area under the plasma
concentration-time profile from time 0 to 4 hours post-
dose (AUC0-4) was determined by the linear/log linear
trapezoidal method.
Proof-of-concept component
The primary efficacy variable was ACR20 (American
College of Rheumatology 20% improvement criteria)
response rate at week 12. Other efficacy variables
included the following: ACR50, ACR70, patient’s assess-
ment of arthritis pain, patient’s global assessment of
arthritis, physician’s global assessment of arthritis, health
assessment questionnaire-disability index, CRP variable
of the four-variable disease activity score using 28 joint
counts (DAS28-4 [CRP]) and the two component scores
of the Short Form-36 (physical and mental component
summary) health questionnaire. Patients had to remain
‘on study, off drug’ up to 28 days after the last dose, at
which time the week 16 visit procedures had to be
completed.
Safety evaluations
Safety was evaluated by monitoring adverse events
(AEs), clinical laboratory evaluations, vital signs, and 12-
lead electrocardiograms (ECGs) and by conducting phy-
sical examinations. All treatment-emergent AEs were
summarized by body system and preferred term within
each treatment group by using the Medical Dictionary
for Regulatory Activities (MedDRA version 11.1; Main-
tenance and Support Services Organization).
Statistical analyses
In the POC component, it was anticipated that 30% of
patients assigned to receive placebo and 55% of patients
assigned to receive maraviroc 300 mg BID would
achieve an ACR20 response at week 12. Sample sizes of
38 patients for the placebo group and 76 patients for
the maraviroc group were considered sufficient to detect
an absolute difference of 25% in ACR20 response with
81% power and a type I error of 0.05 in a one-sided
test, taking the planned futility interim analysis into
account. The primary efficacy endpoint in the POC
component was performed on the full analysis set
(FAS), which was defined as all randomly assigned
patients who received at least one dose of study drug.
ACR20 response rate at week 12 was also analyzed for
the interim analysis set (IAS) and observed cases. Cate-
gorical variables (ACR20, ACR50, and ACR70) were
analyzed by the chi-squared test unless the normal
approximation to the binomial distribution was not
appropriate. If this was the case, the Barnard exact test
was used. Analysis of covariance models, with treatment
and region as fixed effect and baseline as covariate, was




Sixteen patients were randomly assigned and treated in
the safety/PK component: eight patients received mara-
viroc 150 mg BID, and eight patients received maraviroc
300 mg BID in addition to their stable background
MTX treatment (Figure 2A). One patient in the mara-
viroc 150 mg BID group discontinued treatment because
of an AE of worsening RA (moderate).
Of the 112 patients assigned to the POC component,
110 patients were treated: 77 with maraviroc 300 mg
BID and 33 with placebo. Random assignment was
allowed to continue during the interim analysis; hence,
more patients were included in the final data analysis
than in the interim. Of the 198 patients screened for the
CCR5Δ32 mutation in the POC component, only one
patient presented with the homozygous mutation and
was subsequently excluded from the study. In total, 74
(66.1%) patients completed the POC component of the
study, and 14 (42.4%) and 22 (28.6%) patients withdrew
from the placebo and maraviroc treatment groups,
respectively (Figure 2B). The numbers of patients who
withdrew for reasons related to study treatment were
eight (24.2%) and 19 (24.7%) in the placebo and mara-
viroc groups, respectively.
Baseline demographics and characteristics
Baseline patient demographics and characteristics for
both the safety/PK and POC components are shown in
Table 1. The mean ages of patients in the safety/PK
component were 58.5 years (maraviroc 150 mg BID)
and 56.6 years (maraviroc 300 mg BID); for the POC
component, the mean ages were 53.6 and 53.4 years in
the maraviroc 300 mg BID and placebo groups, respec-
tively. While the percentages of males and females in
the safety/PK component were similar, 92.2% of
patients in the maraviroc 300 mg BID group and
66.7% in the placebo group in the POC component
were female. The mean MTX doses were 14.27 mg/
week (range of 7.5 to 30 mg/week) in the POC compo-
nent and 16.41 mg/week (range of 10 to 22.5 mg/
week) in the PK component. The mean durations from
first diagnosis of RA at baseline were similar in the
maraviroc 150 and 300 mg BID groups in the safety/
PK component (11.0 and 11.9 years, respectively) and
in the POC component: 7.8 years (placebo) and 7.9
years (maraviroc 300 mg BID). Patients in the POC
component had moderate to severe active RA with
mean DAS28-4 (CRP) values of 6.0 and 5.8 in the
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placebo and maraviroc treatment groups, respectively.
Components of the DAS were also similar between
placebo and maraviroc 300 mg BID at baseline in the
POC component (Table 1).
Efficacy
An interim analysis was performed when approximately
50% of the total planned patients completed the study.
Fifty-nine patients (38 maraviroc 300 mg BID and 21
Figure 2 Patient disposition. (A) Safety/PK component. (B) Proof-of-concept component. *Discontinued because the study was terminated by
the sponsor. AE, adverse event; BID, twice daily; LOE, lack of efficacy; NLW, no longer willing (to participate in study).
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placebo) completed the week 12 interim analysis visit.
There was no significant difference in the percentage of
ACR20 responders at week 12 in the maraviroc (23.7%)
and placebo (23.8%) groups: difference from placebo of
-0.13; 90% confidence interval (CI) of -20.45 to 17.70; P =
0.504 (IAS). The O’Brien-Fleming futility boundary [19]
(4.5% in observed difference of maraviroc from placebo)
was crossed for the primary analysis of ACR20 response,
and the study was therefore terminated. Random assign-
ment of new patients and study drug administration for all
previously randomly assigned patients was discontinued.
At the final analysis, no significant difference was seen
for the ACR20 response at week 12 (FAS) between mar-
aviroc 300 mg BID (28.4%) and placebo (21.4%):
difference from placebo of 9.09; 90% CI of -6.16 to
21.83; P = 0.155. There was no significant difference
between maraviroc 300 mg BID and placebo groups for
ACR20 response at any time point (Figure 3A).
Sensitivity analyses also failed to demonstrate a signifi-
cant difference. Observed case analysis showed no sig-
nificant difference for ACR20 response at week 12
between maraviroc 300 mg BID (30.0%) and placebo
(19.1%): difference from placebo of 10.95; 90% CI of
-9.50 to 29.05; P = 0.225.
A small percentage of patients exhibited ACR50 and
ACR70 responses throughout the study period. The
numbers of patients with an ACR50 response at at least
one study visit were 11 (15.3%) and four (12.9%) in the
Table 1 Baseline patient demographics and characteristics
Safety/PK component POC component
Maraviroc 150 mg BID (n
= 8)








Female, number (percentage) 4 (50.0) 5 (62.5) 22 (66.7) 71 (92.2) 0.0014
Age in years
Mean (SD) 58.5 (7.8) 56.6 (5.9) 53.4
(11.1)
53.6 (12.1) 0.9274
Range 44-67 46-63 34-76 20-81 -
Race, number (percentage) -
White 8 (100.0) 8 (100.0) 21 (63.6) 51 (66.2)
Black 0 0 0 3 (3.9)
Asian 0 0 5 (15.2) 7 (9.1)
Other 0 0 7 (21.2) 16 (20.8)
Weight in kg, mean (SD) 90.9 (30.4) 88.9 (13.9) 72.7
(16.9)
70.5 (15.4) 0.5173
Height in cm, mean (SD) 164.5 (11.1) 167.4 (4.8) 162.0
(9.7)
159.8 (7.6) 0.2057
BMI in kg/m2, mean (SD) 33.3 (10.2) 31.6 (4.0) 27.6
(5.5)
27.5 (5.4) 0.9670
Duration from first diagnosisb 0.9817
Mean in years 11.0 11.9 7.8 7.9
Range in years 3.0-22.3 2.5-29.0 0.6-32.0 0.4-40.0
ACR components, mean (SD)c
Tender/painful joint count - - 17.5
(6.6)
16.4 (7.3) 0.3565
Swollen joint count - - 12.8
(5.9)
11.5 (4.6) 0.2062










Physician’s global assessment of
arthritis
- - 3.5 (0.7) 3.5 (0.7) 0.7926
HAQ-DI - - 1.7 (0.7) 1.7 (0.6) 0.8405
CRP - - 17.4
(19.0)
14.3 (13.2) 0.6946
DAS28-4 (CRP)c - - 6.0 (0.9) 5.8 (0.8) 0.4554
aTwo-sample t test comparison for proof-of-concept (POC) component demographics. bTo day 1 of study. cAmerican College of Rheumatology (ACR) components
and DAS28-4 (CRP) were not assessed at baseline for the safety/pharmacokinetic (PK) component. BID, twice daily; BMI, body mass index; CRP, C-reactive protein;
DAS28-4 (CRP), disease activity score, 28-joint count, using C-reactive protein; HAQ-DI, health assessment questionnaire-disease index; SD, standard deviation.
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maraviroc and placebo groups, respectively. The num-
bers of patients with an ACR70 response at at least one
study visit were two (2.8%) and three (9.7%) in the mar-
aviroc and placebo groups, respectively.
At week 12, CRP appeared to increase from baseline
in the maraviroc group and decrease from baseline in
the placebo group; however, no significant difference
between the groups was observed at any time point over
12 weeks (Figure 3B). At week 12, the least squares
mean changes from baseline in CRP were 2.35 (mara-
viroc 300 mg BID) and 1.93 (placebo) (P = 0.912).
DAS28-4 (CRP) decreased from baseline in both treat-
ment groups over the 12 week study period (Figure 3C);
at week 12, the least squares mean changes from base-
line were -0.91 (maraviroc 300 mg BID) and -0.64 (pla-
cebo) (P = 0.339). There were no significant differences
at any time point in DAS28-4 (CRP).
Changes from baseline in other efficacy variables at
week 12 are summarized in Table 2. For components of
the ACR20 response, patients in both treatment groups
demonstrated changes in their assessment of arthritis
pain and global assessment of arthritis but not at clini-
cally significant levels.
Safety
Maraviroc was generally well tolerated when given in
combination with stable background doses of MTX in
both the safety/PK and POC components of this study.
Safety/pharmacokinetics component
A total of four (50%) patients in each treatment group
experienced at least one AE. In the maraviroc 150 mg
BID group, two patients reported AEs that were consid-
ered by the study investigator to be treatment-related
(nausea, fatigue, arthralgia, back pain, and muscle
spasms). In the maraviroc 300 mg BID group, one
patient reported treatment-related AEs: abnormal feces
and dry mouth. The AE profile was very similar in both
dosing groups, and no serious or severe AEs, temporary
discontinuations, dose reductions due to AEs, or deaths
were reported. Infections and infestations were reported
in two (25%) patients in the maraviroc 300 mg BID
group, but none was considered treatment-related. Vital
signs and ECG parameters remained stable during the
study period, and no clinically significant changes were
noted. Laboratory abnormalities were reported in six
(75%) and seven (88%) patients in the maraviroc 150 mg
BID and 300 mg BID groups, respectively.
Proof-of-concept component
Treatment-emergent and treatment-related AEs (reported
by at least two patients in either treatment arm) are
shown in Table 3. The majority of AEs were mild to mod-
erate in severity, and a total of 60 (55%) patients reported
at least one treatment-emergent AE. The most common
all-causality treatment-emergent AEs in the maraviroc
group were constipation (7.8%), nausea (5.2%), worsening
RA (3.9%), fatigue (3.9%), upper respiratory tract infection
Figure 3 POC Component: Key Efficacy Endpoints (A) Effect of
maraviroc on ACR20 response rate over time. (B) Least squares
mean change from baseline in CRP over time. (C) Least squares
mean change from baseline in DAS28-4 (CRP) over time; all figures
used data from the full analysis set (FAS) with last observation
carried forward(LOCF). ACR20, American College of Rheumatology
20% improvement criteria; BID, twice daily; CRP, C-reactive protein;
DAS, disease activity score; DAS28-4 (CRP), disease activity score, 28-
joint count, using C-reactive protein; FAS, full analysis set; LOCF, last
observation carried forward; SEM, standard error of the mean.
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(3.9%), and respiratory tract infection (2.6%). In the pla-
cebo group, the most common all-causality treatment-
emergent AEs were worsening RA (24.2%), diarrhea
(6.1%), peripheral edema (6.1%), and influenza (6.1%). No
serious AEs were reported during the study. In the placebo
group, one case of neutropenia, visual impairment, and
ulcer and two cases of RA were classed as severe. In the
maraviroc group, there was one case of humerus fracture
and one of RA, and both were considered to be severe.
Infections and infestations were reported in 10 (13.0%)
patients in the maraviroc 300 mg BID group and five
(15.2%) patients in the placebo group; of these, only one
instance in the placebo group was considered treatment-
related. The most common infections and infestations
were upper respiratory tract infection (three patients in
the maraviroc 300 mg BID group), respiratory tract infec-
tion (two patients in the maraviroc 300 mg BID group),
and influenza (two patients in the placebo group).
There were no clinically significant changes in vital
signs or ECG measurements. Laboratory abnormalities
were reported in 43 (64%) and 17 (61%) patients in the
maraviroc 300 mg BID and placebo groups, respectively,
but were not clinically significant. There was a slight
increase in the cluster of differentiation-8 (CD8) counts
(> 1.1 × upper limit of normal range, or ULN) of the
maraviroc-treated patients (4%) in comparison with pla-
cebo (0%); however, CD4 counts (> 1.1 × ULN) were
similar in both treatment groups. Maraviroc did not
appear to impact hepatic function: there were no grade 2,
3, or 4 shifts in either treatment group for liver
Table 2 Summary of least squares mean (SEM) change from baseline in secondary efficacy endpoints at week 12





Tender/painful joint count -3.41 (1.19) [n = 33] -4.89 (0.84) [n = 77] 0.294
Swollen joint count -3.43 (0.95) [n = 33] -3.48 (0.66) [n = 77] 0.966
Patient’s assessment of arthritis pain -6.09 (4.06) [n = 33] -8.30 (2.85) [n = 77] 0.644
Patient’s global assessment of arthritis -6.78 (4.06) [n = 33] -8.55 (2.88) [n = 76] 0.712
Physician’s global assessment of arthritis -0.36 (0.15) [n = 32] -0.49 (0.11) [n = 75] 0.490
HAQ-DI -0.06 (0.13) [n = 20] -0.18 (0.08) [n = 55] 0.396
SF-36 version 2 (acute)
Physical component summary 4.81 (1.65) [n = 19] 3.14 (1.04) [n = 53] 0.344
Mental component summary 0.61 (2.25) [n = 19] 1.17 (1.41) [n = 53] 0.818
ACR, American College of Rheumatology; BID, twice daily; FAS, full analysis set; HAQ-DI, health assessment questionnaire-disability index; LOCF, last observation
carried forward; SEM, standard error of the mean; SF-36, Short Form-36 Health Survey.
Table 3 Summary of treatment-emergent and treatment-related adverse events by preferred term reported by at least
two patients in either treatment group (proof-of-concept component)









Worsening rheumatoid arthritis 8 (24.2) 1 (3.0) 3 (3.9) 0
Constipation 0 0 6 (7.8) 4 (5.2)
Nausea 0 0 4 (5.2) 3 (3.9)
Chills 1 (3.0) 0 2 (2.6) 2 (2.6)
Dizziness 1 (3.0) 1 (3.0) 2 (2.6) 1 (1.3)
Fatigue 0 0 3 (3.9) 1 (1.3)
Edema peripheral 2 (6.1) 2 (6.1) 0 0
Headache 1 (3.0) 0 2 (2.6) 1 (1.3)
Diarrhea 2 (6.1) 0 1 (1.3) 1 (1.3)
Upper respiratory tract infection 0 0 3 (3.9) 0
Orthostatic hypotension 0 0 2 (2.6) 1 (1.3)
Dyspepsia 0 0 2 (2.6) 1 (1.3)
Pyrexia 0 0 2 (2.6) 1 (1.3)
Respiratory tract infection 0 0 2 (2.6) 0
Influenza 2 (6.1) 0 0 0
BID, twice daily.
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transaminases; the only significant alanine transaminase
(ALT) elevation (> 3.0 × ULN) occurred in the placebo
group.
Pharmacokinetics and pharmacogenomics
Concomitant administration of MTX and maraviroc
(150 or 300 mg BID) did not result in altered MTX
exposure in patients with RA. After oral administration
of maraviroc, absorption was rapid, and a median Tmax
ranged from 2 to 2.5 hours in both doses studied.
Increases in both AUC and Cmax were approximately
proportional to the dose increases. Between-patient
variability were 48% (150 mg BID) and 74% (300 mg
BID) for AUC0-4 and 50% (150 mg BID) and 67% (300
mg BID) for Cmax. MTX concentration profiles at
screening and 1 week after initiation of maraviroc were
similar in both treatment groups. The changes in MTX
exposure (based on the ratio of AUCs) were 0.96 and
1.18 after concomitant administration of maraviroc 150
mg BID and 300 mg BID, respectively. This magnitude
of change in systemic exposure was not considered to
be clinically relevant.
Discussion
The objectives of this study were to evaluate the safety/
PK profile of maraviroc in patients with RA and to
investigate whether maraviroc-induced CCR5 antagon-
ism reduces disease activity in these patients. The study
demographic characteristics were generally well
balanced, with the exception of the larger percentage of
females in the maraviroc-treated subjects in the POC
component. While this could have had some effect on
treatment outcome, it is unlikely that the gender imbal-
ance led to the lack of treatment effect observed in this
trial.
The study stopped at a planned interim analysis
because of futility. These findings were confirmed by
the final analysis, demonstrating that there was no sig-
nificant effect on ACR responder rates, CRP, or DAS.
These results support a recent POC study that also
demonstrated a lack of supporting evidence for the use
of a CCR5 blockade as a therapeutic target in patients
with active RA [20].
Given the well-documented action of maraviroc on
CCR5 (a receptor that may play an important role in
RA) [1], it is somewhat surprising that no significant
improvements in the primary or secondary efficacy vari-
ables were observed in this study, as the maraviroc dose
has demonstrated greater than 90% receptor occupancy
[21].
One possible explanation may be that selective antag-
onism of CCR5 is insufficient to significantly improve
all of the measures assessed in this study; blocking a
number of chemokines may be necessary. This was
postulated by van Kuijk and colleagues [20], who noted
that the blockade of CCR1 or CCR2 alone yielded no
significant improvement in RA. Alternatively, CCR5 may
not be a relevant mechanism in the progression of RA.
Another consideration is the timing of this intervention.
Patients enrolled in the POC component of this study
had a mean disease duration of nearly 8 years and had
persistent disease activity despite treatment with MTX;
this may be too late in the course of RA. Part of the
rationale for studying maraviroc in patients with RA is
the apparent protective effect conferred by the Δ32
mutation of CCR5 [14-16]. However, it may be that
therapeutic intervention is required before the disease is
clinically evident in order to be effective. It is also possi-
ble that the physiologic effects of this genetic deletion
are different from those elicited by CCR5 antagonism
with an oral small-molecule inhibitor after the onset of
the disease. Furthermore, as corticosteroids are thought
to affect leukocyte trafficking [22,23], it may be useful to
compare efficacy profiles between those patients treated
with concomitant corticosteroids and those who are not.
In the present study, approximately 51% of patients
received a corticosteroid during the trial; however, the
numbers were too small to carry out a statistical
comparison.
Results from the safety/PK portion of this study
demonstrated that maraviroc 150 and 300 mg BID were
well tolerated over 4 weeks and not associated with a
DDI with MTX. In addition, there was no evidence to
suggest that maraviroc meaningfully alters the PK dispo-
sition of MTX in patients with RA. The Cmax of mara-
viroc observed in this study was comparable to that
achieved in asymptomatic patients with HIV but lower
than that in healthy volunteers; Tmax values were com-
parable to those in healthy volunteers [24]. As the safety
and PK profiles of maraviroc 150 and 300 mg were
similar and there was no evidence of a DDI with MTX,
the 300-mg dose was selected for administration in the
12-week POC component.
Results from the POC component of the study indi-
cate that combined maraviroc 300 mg BID and MTX
treatment was generally well tolerated and that the AE
profile was very similar to that of both healthy volun-
teers and treatment-experienced patients infected with
CCR5-tropic HIV in the early-phase I/II studies in the
HIV indication [25,26], pivotal phase III studies [27],
and postmarketing surveillance (data on file). Maraviroc
was well tolerated in patients with RA, and there were
no safety concerns in this study. Several early studies
highlighted concerns about the possible class-specific,
long-term hepatotoxic side effects of CCR5 antagonists
[5,28], and the prescribing information for maraviroc
contains a black-box warning for hepatotoxicity [24];
however, these warnings initially stemmed from studies
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using the chemokine antagonist, aplaviroc, in which sev-
eral cases of severe liver toxicity emerged in patients
receiving the drug, and trials were halted [29,30]. How-
ever, Nichols and colleagues [30] suggested that the
hepatotoxicity of aplaviroc could be idiosyncratic rather
than CCR5-mediated, as it was observed in animal mod-
els in which aplaviroc does not bind to CCR5. In the
present study, even with the co-administration of MTX,
there were no commonly reported AEs associated with
hepatic function. Similarly, there were no discontinua-
tions due to liver function in the maraviroc group, sup-
porting other investigations of maraviroc in the HIV
indication [31]. In addition, known systemic allergic
symptoms that may precede idiosyncratic hepatotoxicity
of allergic origin (such as elevation of eosinophils and
incidence of an itchy rash) [26] were low (eosinophils)
or nonexistent (rash).
Conclusions
In summary, maraviroc 300 mg BID demonstrated an
acceptable safety profile and was well tolerated but was
not clinically efficacious in patients who had active RA
and who were on background MTX.
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